Core Laboratories Stock 5-Day Winning Spree: Stock Climbs 49%
Core Laboratories (CLB) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 49% return. The company has gained about $255 Mil in value over the last 5 days, with its current market capitalization at about $780 Mil. The stock remains 2.4% below its value at the end of 2024. This compares with year-to-date returns of 15.5% for the S&P 500.
CLB provides reservoir description and production enhancement services and products to the oil and gas industry through specialized segments. After this rally, is CLB still a buy – or is it time to lock in gains? Deep dive with Buy or Sell CLB.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Strategic asset allocation and diversification help you stay invested. Did you know investors who panicked out of the S&P in 2020 lost significant upside that followed? Trefis High Quality Portfolio and Empirical Asset Management’s asset allocation approach are designed to reduce volatility so you can stay the course.
Comparing CLB Stock Returns With The S&P 500
The following table summarizes the return for CLB stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CLB | S&P 500 |
|---|---|---|
| 1D | 2.5% | 0.8% |
| 5D (Current Streak) | 48.7% | 1.9% |
| 1M (21D) | 36.0% | 2.8% |
| 3M (63D) | 41.1% | 6.3% |
| YTD 2025 | -2.4% | 15.5% |
| 2024 | -1.8% | 23.3% |
| 2023 | -12.7% | 24.2% |
| 2022 | -9.0% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has CLB behaved after prior drops? See CLB Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 37 S&P constituents with 3 days or more of consecutive gains and 51 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 33 |
| 4D | 4 | 14 |
| 5D | 2 | 4 |
| 6D | 6 | 0 |
| 7D or more | 4 | 0 |
| Total >=3 D | 37 | 51 |
Key Financials for Core Laboratories (CLB)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $509.8 Mil | $523.8 Mil |
| Operating Income | $55.2 Mil | $49.8 Mil |
| Net Income | $36.7 Mil | $31.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $130.2 Mil | $134.5 Mil |
| Operating Income | $12.3 Mil | $15.3 Mil |
| Net Income | $10.6 Mil | $14.2 Mil |
While CLB stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.